Market Place
Sourcing Support
All News #Library
Others
IO Biotech Reports Q1 2025 Financial Results and Highlights
14 May 2025 //
GLOBENEWSWIRE
IO Bio Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Melanoma
10 Nov 2023 //
GLOBENEWSWIRE
IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations
09 Nov 2022 //
GLOBENEWSWIRE
IO Biotech Announces Clinical Collaboration with Merck to Evaluate Neoadjuvant
03 Nov 2022 //
GLOBENEWSWIRE
IO Biotech to Participate in the Jefferies London Healthcare Conference
31 Oct 2022 //
GLOBENEWSWIRE
IO Biotech Announces Appointment of New Chief Financial Officer
13 Oct 2022 //
GLOBENEWSWIRE
IO Biotech Announces Invited Oral Presentation and Two Poster Presentations
05 Oct 2022 //
GLOBENEWSWIRE
IO Biotech Announces Second Quarter Results for 2022
11 Aug 2022 //
GLOBENEWSWIRE
IO Biotech to Participate in the 2022 BIO International Convention
06 Jun 2022 //
GLOBENEWSWIRE
IO Biotech Announces Two Presentations at the ASCO 2022
26 May 2022 //
GLOBENEWSWIRE
IO Biotech to Participate in the Jefferies Healthcare Conference
23 May 2022 //
GLOBENEWSWIRE
IO Biotech Initiates PIII Combination Trial of IO102-IO103 and KEYTRUDA
18 May 2022 //
GLOBENEWSWIRE
IO Biotech Announces First Quarter Results for 2022
16 May 2022 //
GLOBENEWSWIRE
IO Biotech Initiates PII Trial of IO102-IO103+ KEYTRUDA as 1L Treatment
12 Apr 2022 //
GLOBENEWSWIRE
IO Biotech Presents New Data from MM1636 Phase 1/2 Trial at AACR
08 Apr 2022 //
GLOBENEWSWIRE
IO Biotech Announces Year-End Results for 2021
31 Mar 2022 //
GLOBENEWSWIRE
IO Biotech says Acceptance of Abstract to be Presented at AACR
08 Mar 2022 //
GLOBENEWSWIRE
IO Biotech to Present at 42nd Annual Cowen Healthcare Conference
04 Mar 2022 //
GLOBENEWSWIRE
IO Biotech Announces Appointment of David V. Smith to its Board of Directors
03 Mar 2022 //
GLOBENEWSWIRE
IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results
09 Dec 2021 //
GLOBENEWSWIRE
IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise
09 Nov 2021 //
GLOBENEWSWIRE
Immuno-oncology biotech IO Biotech files for a $100 million IPO
15 Oct 2021 //
RENAISSANCECAPITAL
IO Biotech & MSD Collaborate for IO102-IO103 + KEYTRUDA in Metastatic Melanoma
14 Sep 2021 //
PRNEWSWIRE
IO Biotech raises $155M to trial IDO and PD-L1 cancer vaccines
13 Jan 2021 //
FIERCEBIOTECH
IO Biotech Announces Phase 2 Clinical Melanoma Data with CR Rate of 45%
18 Sep 2020 //
BIOSPACE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.